These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 30132980)

  • 1. What influences placebo and nocebo responses in Parkinson's disease?
    Witek N; Stebbins GT; Goetz CG
    Mov Disord; 2018 Aug; 33(8):1204-1212. PubMed ID: 30132980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors influencing the outcome of deep brain stimulation: Placebo, nocebo, lessebo, and lesion effects.
    Mestre TA; Lang AE; Okun MS
    Mov Disord; 2016 Mar; 31(3):290-6. PubMed ID: 26952118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nocebo and lessebo effects.
    A Mestre T
    Int Rev Neurobiol; 2020; 153():121-146. PubMed ID: 32563285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Placebo and nocebo responses in other movement disorders besides Parkinson's disease: How much do we know?
    Ferreira JJ; Trenkwalder C; Mestre TA
    Mov Disord; 2018 Aug; 33(8):1228-1235. PubMed ID: 30230626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nocebo response in Parkinson's disease: A systematic review and meta-analysis.
    Leal Rato M; Duarte GS; Ferreira AN; Alves M; Mainoli B; Teodoro T; Mestre TA; Costa J; Ferreira JJ
    Parkinsonism Relat Disord; 2019 Aug; 65():13-19. PubMed ID: 31103487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Harnessing the power of placebos in movement disorders: Insights from Parkinson's disease in clinical research and practice.
    Mestre TA; Shamy M; Benedetti F; Lang AE
    Mov Disord; 2018 Aug; 33(8):1195-1203. PubMed ID: 30145820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Motor and cognitive placebo-/nocebo-responses in Parkinson's disease patients with deep brain stimulation.
    Keitel A; Wojtecki L; Hirschmann J; Hartmann CJ; Ferrea S; Südmeyer M; Schnitzler A
    Behav Brain Res; 2013 Aug; 250():199-205. PubMed ID: 23651878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Catechol-O-methyltransferase Val158Met polymorphism is associated with somatosensory amplification and nocebo responses.
    Wendt L; Albring A; Benson S; Engler H; Engler A; Hinney A; Rief W; Witzke O; Schedlowski M
    PLoS One; 2014; 9(9):e107665. PubMed ID: 25222607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Placebo and nocebo effect: a mini-review.
    Požgain I; Požgain Z; Degmečić D
    Psychiatr Danub; 2014 Jun; 26(2):100-7. PubMed ID: 24909245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nocebo Responses in Brain Diseases: A Systematic Review of the Current Literature.
    Zis P; Mitsikostas DD
    Int Rev Neurobiol; 2018; 139():443-462. PubMed ID: 30146057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonmotor symptoms evolution during 24 months of bilateral subthalamic stimulation in Parkinson's disease.
    Dafsari HS; Silverdale M; Strack M; Rizos A; Ashkan K; Mahlstedt P; Sachse L; Steffen J; Dembek TA; Visser-Vandewalle V; Evans J; Antonini A; Martinez-Martin P; Ray-Chaudhuri K; Timmermann L;
    Mov Disord; 2018 Mar; 33(3):421-430. PubMed ID: 29465787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Placebo and Nocebo Phenomena: Their Clinical Management and Impact on Treatment Outcomes.
    Chavarria V; Vian J; Pereira C; Data-Franco J; Fernandes BS; Berk M; Dodd S
    Clin Ther; 2017 Mar; 39(3):477-486. PubMed ID: 28237673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Lessebo Effect in Disease Modification Trials in Parkinson's Disease.
    Mestre TA; McDermott MP; Lobo R; Ferreira JJ; Lang AE
    Mov Disord; 2023 Jul; 38(7):1346-1350. PubMed ID: 37093589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The placebo-nocebo response: controversies and challenges from clinical and research perspective.
    Jakovljevic M
    Eur Neuropsychopharmacol; 2014 Mar; 24(3):333-41. PubMed ID: 24393653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Placebo responses in Parkinson's disease.
    Lou JS
    Int Rev Neurobiol; 2020; 153():187-211. PubMed ID: 32563288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurobiology of placebo effect in Parkinson's disease: What we have learned and where we are going.
    Quattrone A; Barbagallo G; Cerasa A; Stoessl AJ
    Mov Disord; 2018 Aug; 33(8):1213-1227. PubMed ID: 30230624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Placebo and nocebo responses in drug trials of epilepsy.
    Zaccara G; Giovannelli F; Schmidt D
    Epilepsy Behav; 2015 Feb; 43():128-34. PubMed ID: 25703333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Great expectations: the placebo effect in Parkinson's disease.
    Lidstone SC
    Handb Exp Pharmacol; 2014; 225():139-47. PubMed ID: 25304530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Placebo and nocebo effects in the neurological practice.
    Bittar C; Nascimento OJ
    Arq Neuropsiquiatr; 2015 Jan; 73(1):58-63. PubMed ID: 25608129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Placebo and nocebo reactions in randomized trials of pharmacological treatments for persistent depressive disorder. A meta-regression analysis.
    Meister R; Jansen A; Härter M; Nestoriuc Y; Kriston L
    J Affect Disord; 2017 Jun; 215():288-298. PubMed ID: 28363152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.